Add to ORKGThe clinical and neurophysiologic data from 65 patients taking thalidomide were reviewed. Thalidomide sensory neurotoxicity was found to be cumulative dose dependent but occurs only when the total dose is relatively high (>20 g). The risk of developing sensory neuropathy is around 10% below this threshold but increases with higher doses
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
Thalidomide is a drug whose efficacy been reported in numerous conditions which can be attributable ...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
Background: Peripheral neuropathy (PN), the most common complication during thalidomide (TD) treatm...
In 1960 it became apparent that patients who had taken thalidomide regularly as a nocturnal sedative...
BACKGROUND: Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (...
BACKGROUND: Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (...
OBJECTIVE: Thalidomide is remarkably active in advanced relapsed and refractory multiple myeloma (MM...
Review of the various drugs in current clinical use showed that over 50 of them may cause a purely s...
Thalidomide has several targets and mechanisms of action: a hypnosedative effect, several immunomodu...
OBJECTIVE: To evaluate long-term lenalidomide neurotoxicity and correlation with cumulative dose a...
Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM). We prese...
Background: Thalidomide is used in cutaneous lupus erythematosus (CLE) refractory to conventional th...
textabstractPeripheral neurotoxicity is an important side-effect of several chemotherapeutic agents....
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
Thalidomide is a drug whose efficacy been reported in numerous conditions which can be attributable ...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
Background: Peripheral neuropathy (PN), the most common complication during thalidomide (TD) treatm...
In 1960 it became apparent that patients who had taken thalidomide regularly as a nocturnal sedative...
BACKGROUND: Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (...
BACKGROUND: Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (...
OBJECTIVE: Thalidomide is remarkably active in advanced relapsed and refractory multiple myeloma (MM...
Review of the various drugs in current clinical use showed that over 50 of them may cause a purely s...
Thalidomide has several targets and mechanisms of action: a hypnosedative effect, several immunomodu...
OBJECTIVE: To evaluate long-term lenalidomide neurotoxicity and correlation with cumulative dose a...
Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM). We prese...
Background: Thalidomide is used in cutaneous lupus erythematosus (CLE) refractory to conventional th...
textabstractPeripheral neurotoxicity is an important side-effect of several chemotherapeutic agents....
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
Thalidomide is a drug whose efficacy been reported in numerous conditions which can be attributable ...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...